Injectable Drugs DeepDive 2021 • JDF746K • January 2021 • US$4,850
This report is a comprehensive evaluation and analysis of the products and participants in this evolving segment of the therapeutic drug sector. It is designed to provide drug product decision makers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, disease segments, and commercial opportunities for injectables. These products are marketed and supplied by slightly less than one hundred companies. Competition among the various drug and therapeutic classes is uneven, with the top ten segments accounting for a disproportionate level of activity and revenue. Understanding the underlying factors affecting business performance is key to attaining financial targets. Provider organization business managers, healthcare administrators and investors will also benefit from this study.
Injectable Drugs DeepDive – What You Will Learn
• What are the dynamics of the shifting landscape for injectable drugs?
• Provides assessments of FDA-approved injectable drugs assesses key market segments, market dynamics
and potential product opportunities
• Who are the leading injection device companies, and what are their business strategies?
• Presents the competitive picture injectables in two dozen drug classes
• Evaluates the importance of ANDA/NDA/BLA filing strategies on participant growth prospects
• Assesses the market presence and product position of the top twenty-four injectables suppliers
• Evaluates the impact of economic, technology, and regulatory factors
Summary of Contents
Injectables Market Opportunities
Injectable Drug Market Segment
FDA-Approved Injectable Drugs – Market Segment Therapeutics
Injectable Drug APIs – Product Opportunity Charts
Injectable Recombinant Proteins
Company Activity Summaries
For more information click HERE